EUCTR2009-011739-11-FRActive, not recruitingPhase 1
Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squamous, Non-Small Cell Lung Cancer - A Study in Patients with Non-Small Cell Lung Cancer
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •[1]Histologic or cytologic diagnosis of unresectable nonsquamous Stage IIIA or Stage IIIB NSCLC. Squamous cell and/or mixed small cell, non-small cell histology is not permitted.
- •[2]Have an ECOG PS of 0 or 1.
- •[3]Previous radiation therapy is allowed, but should have been limited and must not have included thoracic radiation, whole pelvis radiation, or radiation to >25% of the patient’s bone marrow. Patients must have recovered from the toxic effects of radiation treatment prior to study enrollment. Prior radiotherapy must be completed 30 days before study entry.
- •[4]Have at least 1 unidimensionally measurable lesion meeting RECIST guidelines, version 1.0. Positron emission tomography (PET) scans and ultrasounds may not be used.
- •[5]Estimated life expectancy of at least 12 weeks.
- •[6]Patient compliance and geographic proximity that allow adequate follow-up.
- •[7]Adequate organ function, including the following:
- •Adequate bone marrow reserve, adequate hepatic, pulmonary and renal functions.
- •[8]Patients must sign an ICD.
- •[9]Patients must be at least 18 years of age.
- •[10]Patients must have completed a 3-D plan, and the attending physician must have reviewed and approved the dose volume histograms with a total lung V20 < or = 35%.
- •[11]For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen during and for 6 months after the treatment period; must have a negative serum pregnancy test within 7 days before study enrollment and must not be breast-feeding.
- •For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.
- •[12] Have not received prior systemic anticancer therapy for NSCLC. No prior adjuvant chemotherapy is allowed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •[13]Have received treatment within the last 30 days of enrollment with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[14]Have previously completed or withdrawn from this study or any other study investigating pemetrexed.
- •[15]Have a serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol.
- •[16]Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.
- •[17]Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Patients with a history of low-grade (Gleason score < or = 6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously.
- •[18]Are receiving concurrent administration of any other antitumor therapy.
- •[19]Have had weight loss > 10% over the previous 3 months before study entry.
- •[20]Are unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose < or = 1.3 grams per day, for at least 2 days before (5 days for long-acting agents), the day of, and for at least 2 days after administration of pemetrexed.
- •[21]Are unable or unwilling to take folic acid or vitamin B12 supplementation.
- •[22]Are unable or unwilling to take corticosteroids.
- •[23]Have received a recent yellow fever vaccination (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination.
- •[24]Have known hypersensitivity to pemetrexed, cisplatin, or any of the excipients in these medicinal products.
- •[25]Have evidence of clinical hearing loss.
- •[26]Have clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squamous, Non-Small Cell Lung Cancer - A Study in Patients with Non-Small Cell Lung Canceron-small Cell Lung CancerMedDRA version: 9.1Level: LLTClassification code 10029520Term: Non-small cell lung cancer stage IIIAMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBEUCTR2009-011739-11-DEEli Lilly and Company Limited88
Active, not recruiting
Not Applicable
Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squamous, Non-Small Cell Lung Cancer - NDEUCTR2009-011739-11-ITEli Lilly and Company Limited88
Active, not recruiting
Not Applicable
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
Active, not recruiting
Phase 1
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-NLEli Lilly and Company113
Active, not recruiting
Not Applicable
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-DEEli Lilly and Company125